|
|
|
|
||
2021 Kidney Week Journal - 4326 info From page 402 of the 2021 Kidney Week Journal. It's 906 pages long, so be forewarned if you download it. RGLS4326 Increases Urinary PC1 and PC2 Levels in Individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Edmund Lee,1 Tania M. Valencia,1 Tate Owen,1 Steven Neben,1 Karl F. Cremer,1 Rekha Garg,4 Denis Drygin,1 Christopher J. Ward,2 Alan S. Yu,2 Vishal Patel.3 1Regulus Therapeutics Inc, San Diego, CA; 2University of Kansas Medical Center, Kansas City, KS; 3The University of Texas Southwestern Medical Center Department of Internal Medicine, Dallas, TX; 4PharmaDRS Consulting LLC, San Diego, CA. Background: ADPKD is caused by mutations of either PKD1 or PKD2 genes, leading to reduced function of their respective protein products PC1 and PC2. Both proteins are secreted in exosomes, and their urinary levels inversely correlate with ADPKD severity. RGLS4326, a novel oligonucleotide inhibitor of miR-17, preferentially delivers to kidney tubules and cysts, derepresses miR-17 targets Pkd1 and Pkd2, increases PC1 and PC2, and attenuates cyst growth in multiple PKD mouse models. Whether RGLS4326 treatment would increase PC1 and PC2 in individuals with ADPKD was unknown. Methods: An open-label, adaptive design, dose-ranging, Phase 1b clinical study is ongoing to evaluate RGLS4326 safety, pharmacodynamics and pharmacokinetics in individuals with ADPKD. The study will enroll ~27 patients (9 per cohort) treated subcutaneously with one of three RGLS4326 doses (1, 0.3, and 0.1 or 0.5 mg/kg Q2W x 4 doses) and will be followed for 28 days after the last dose (Day 71). The major inclusion criteria are Mayo Imaging Classification of 1C, 1D, or 1E, and GFR between 30-90 mL/min/ 1.73 m2. The urinary biomarkers include PC1 and PC2 on exosomes, kidney injury marker 1 (KIM1), and neutrophil gelatinase-associated lipocalin (NGAL). Results: Nine patients (mean GFR 49 mL/min/1.73m2, mean age 50 yr) were enrolled in the first cohort; each patient received four doses of 1mg/kg of RGLS4326 Q2W. RGLS4326 was well tolerated with no serious adverse events. PK profiles were similar to healthy volunteers, with a plasma half-life of 9 hours and plasma AUC levels after the first and fourth dose ~2x higher in patients. Changes in both PC1 and PC2 at the end of study from baseline were statistically significant (p=0.0004 and p=0.026, respectively), with mean % increase in PC1 and PC2 of 58% and 38%, respectively. Conclusions: These data provide clinical proof that RGLS4326 delivers to cystic kidneys of individuals with ADPKD, where it inhibits miR-17 and thereby derepresses PC1 and PC2. The results also imply ongoing miR-17-mediated repression of Pkd1 and Pkd2 in humans, further validating miR-17 as a therapeutic target for ADPKD treatment. Funding: Commercial Support - Regulus Therapeutics |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
761 | Re: 2021 Kidney Week Journal - 4326 info | arthurs1 | 0 | 10/30/2021 5:46:48 PM |